Table 2.
Plaque changes by treatment group
| Treatment group | Baseline | Follow-up | Difference | GLM modelling |
|||
|---|---|---|---|---|---|---|---|
| Plaque type | Mean (SD) a | Mean (SD)a | Mean (SD)a | Unadj. P | Adj. P | %chg | |
| Calcification | IPE | 3.6 (2.0) | 3.6 (1.9) | 0.0 (0.5) | 0.0464 | 0.0531 | −1% |
| Placebo | 2.9 (1.9) | 3.3 (2.1) | 0.4 (1.2) | 15% | |||
| Fibro-fatty | IPE | 2.7 (1.5) | 1.8 (1.7) | −0.9 (1.3) | <0.0001 | 0.0002 | −34% |
| Placebo | 1.5 (1.5) | 2 (1.5) | 0.5 (1.4) | 32% | |||
| Fibrous | IPE | 4.2 (1.6) | 3.3 (1.6) | −0.9 (1.1) | 0.0012 | 0.0028 | −20% |
| Placebo | 3.3 (1.3) | 3.3 (1.5) | 0.0 (1.0) | 1% | |||
| Low-attenuation plaque | IPE | 1.9 (1.8) | 1.6 (1.7) | −0.3 (1.5) | 0.0037 | 0.0061 | −17% |
| Placebo | 0.8 (1.5) | 1.6 (1.8) | 0.9 (1.7) | 109% | |||
| Total non-calcified plaque | IPE | 4.5 (1.7) | 3.9 (1.3) | −0.8 (1.2) | 0.0002 | 0.0005 | −19% |
| Placebo | 3.5 (1.6) | 3.6 (1.5) | 0.3 (1.3) | 9% | |||
| Total plaque | IPE | 5.0 (1.8) | 4.5 (1.8) | −0.5 (0.8) | 0.001 | 0.0019 | −9% |
| Placebo | 4.1 (1.8) | 4.6 (1.4) | 0.4 (1.2) | 11% | |||
a
Volumes reported are log adjusted mm3, GLM adjusted for age, gender, diabetes mellitus, hypertension, triglyceride level at baseline. GLM, generalized linear model.